Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 115.81
ZLTQ's Cash to Debt is ranked higher than
69% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. ZLTQ: 115.81 )
ZLTQ' s 10-Year Cash to Debt Range
Min: 6.45   Max: No Debt
Current: 115.81

Equity to Asset 0.67
ZLTQ's Equity to Asset is ranked higher than
55% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ZLTQ: 0.67 )
ZLTQ' s 10-Year Equity to Asset Range
Min: -5.35   Max: 0.89
Current: 0.67

-5.35
0.89
F-Score: 7
Z-Score: 19.86
M-Score: -1.97
WACC vs ROIC
5.64%
30.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 3.92
ZLTQ's Operating margin (%) is ranked higher than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. ZLTQ: 3.92 )
ZLTQ' s 10-Year Operating margin (%) Range
Min: -1082.23   Max: 1.22
Current: 3.92

-1082.23
1.22
Net-margin (%) 3.45
ZLTQ's Net-margin (%) is ranked higher than
55% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. ZLTQ: 3.45 )
ZLTQ' s 10-Year Net-margin (%) Range
Min: -1111.78   Max: 0.88
Current: 3.45

-1111.78
0.88
ROE (%) 10.38
ZLTQ's ROE (%) is ranked higher than
73% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. ZLTQ: 10.38 )
ZLTQ' s 10-Year ROE (%) Range
Min: -195.78   Max: 2.3
Current: 10.38

-195.78
2.3
ROA (%) 7.15
ZLTQ's ROA (%) is ranked higher than
75% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: -0.11 vs. ZLTQ: 7.15 )
ZLTQ' s 10-Year ROA (%) Range
Min: -103.26   Max: 1.6
Current: 7.15

-103.26
1.6
ROC (Joel Greenblatt) (%) 57.12
ZLTQ's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. ZLTQ: 57.12 )
ZLTQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1849.11   Max: 26.11
Current: 57.12

-1849.11
26.11
Revenue Growth (3Y)(%) -22.30
ZLTQ's Revenue Growth (3Y)(%) is ranked lower than
91% of the 185 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ZLTQ: -22.30 )
ZLTQ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -68.6   Max: -22.3
Current: -22.3

-68.6
-22.3
» ZLTQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ZLTQ Guru Trades in Q2 2014

RS Investment Management 1,348,166 sh (+15.68%)
Steven Cohen 577,600 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

ZLTQ Guru Trades in Q3 2014

Paul Tudor Jones 11,126 sh (New)
Steven Cohen 635,700 sh (+10.06%)
RS Investment Management 1,170,166 sh (-13.20%)
» More
Q4 2014

ZLTQ Guru Trades in Q4 2014

Steven Cohen 1,299,930 sh (+104.49%)
Paul Tudor Jones 12,767 sh (+14.75%)
RS Investment Management 736,886 sh (-37.03%)
» More
Q1 2015

ZLTQ Guru Trades in Q1 2015

Steven Cohen 1,964,508 sh (+209.03%)
Steven Cohen 1,150,721 sh (-11.48%)
Paul Tudor Jones 8,793 sh (-31.13%)
RS Investment Management 484,116 sh (-34.30%)
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 162.00
ZLTQ's P/E(ttm) is ranked lower than
117% of the 151 Companies
in the Global Medical Devices industry.

( Industry Median: 25.30 vs. ZLTQ: 162.00 )
ZLTQ' s 10-Year P/E(ttm) Range
Min: 162   Max: 1567.27
Current: 162

162
1567.27
Forward P/E 121.95
ZLTQ's Forward P/E is ranked lower than
94% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 22.03 vs. ZLTQ: 121.95 )
N/A
PE(NRI) 175.40
ZLTQ's PE(NRI) is ranked lower than
94% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 28.80 vs. ZLTQ: 175.40 )
ZLTQ' s 10-Year PE(NRI) Range
Min: 175.44   Max: 1724
Current: 175.4

175.44
1724
P/B 14.60
ZLTQ's P/B is ranked lower than
135% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ZLTQ: 14.60 )
ZLTQ' s 10-Year P/B Range
Min: 1.79   Max: 19.19
Current: 14.6

1.79
19.19
P/S 5.50
ZLTQ's P/S is ranked lower than
103% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. ZLTQ: 5.50 )
ZLTQ' s 10-Year P/S Range
Min: 0.17   Max: 7.96
Current: 5.5

0.17
7.96
PFCF 145.70
ZLTQ's PFCF is ranked lower than
132% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. ZLTQ: 145.70 )
ZLTQ' s 10-Year PFCF Range
Min: 145.7   Max: 190.83
Current: 145.7

145.7
190.83
POCF 122.04
ZLTQ's POCF is ranked lower than
93% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 20.43 vs. ZLTQ: 122.04 )
ZLTQ' s 10-Year POCF Range
Min: 122.04   Max: 149.35
Current: 122.04

122.04
149.35
EV-to-EBIT 136.51
ZLTQ's EV-to-EBIT is ranked lower than
93% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 22.45 vs. ZLTQ: 136.51 )
ZLTQ' s 10-Year EV-to-EBIT Range
Min: -231.8   Max: 655
Current: 136.51

-231.8
655
Current Ratio 2.71
ZLTQ's Current Ratio is ranked higher than
53% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. ZLTQ: 2.71 )
ZLTQ' s 10-Year Current Ratio Range
Min: 1.09   Max: 8.26
Current: 2.71

1.09
8.26
Quick Ratio 2.18
ZLTQ's Quick Ratio is ranked higher than
53% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. ZLTQ: 2.18 )
ZLTQ' s 10-Year Quick Ratio Range
Min: 0.78   Max: 7.87
Current: 2.18

0.78
7.87
Days Inventory 111.76
ZLTQ's Days Inventory is ranked higher than
60% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 130.93 vs. ZLTQ: 111.76 )
ZLTQ' s 10-Year Days Inventory Range
Min: 46.43   Max: 109.81
Current: 111.76

46.43
109.81
Days Sales Outstanding 45.89
ZLTQ's Days Sales Outstanding is ranked higher than
80% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 67.63 vs. ZLTQ: 45.89 )
ZLTQ' s 10-Year Days Sales Outstanding Range
Min: 8.79   Max: 237.12
Current: 45.89

8.79
237.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 154.30
ZLTQ's Price/Net Cash is ranked lower than
141% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZLTQ: 154.30 )
ZLTQ' s 10-Year Price/Net Cash Range
Min: 3.49   Max: 181.35
Current: 154.3

3.49
181.35
Price/Net Current Asset Value 30.10
ZLTQ's Price/Net Current Asset Value is ranked lower than
120% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZLTQ: 30.10 )
ZLTQ' s 10-Year Price/Net Current Asset Value Range
Min: 2.79   Max: 21.41
Current: 30.1

2.79
21.41
Price/Tangible Book 16.00
ZLTQ's Price/Tangible Book is ranked lower than
135% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 3.10 vs. ZLTQ: 16.00 )
ZLTQ' s 10-Year Price/Tangible Book Range
Min: 2.32   Max: 14.86
Current: 16

2.32
14.86
Price/Median PS Value 1.70
ZLTQ's Price/Median PS Value is ranked lower than
101% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. ZLTQ: 1.70 )
ZLTQ' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 2.04
Current: 1.7

0.07
2.04
Price/Graham Number 10.30
ZLTQ's Price/Graham Number is ranked lower than
133% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. ZLTQ: 10.30 )
ZLTQ' s 10-Year Price/Graham Number Range
Min: 12.14   Max: 22.69
Current: 10.3

12.14
22.69
Earnings Yield (Greenblatt) 0.70
ZLTQ's Earnings Yield (Greenblatt) is ranked lower than
52% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ZLTQ: 0.70 )
ZLTQ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 0.7
Current: 0.7

0.2
0.7

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
ZELTIQ Aesthetics Inc was incorporated in the state of Delaware on March 22, 2005. In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company generates revenue from sales of CoolSculpting system and from sales of consumables to its customers. Its geographical region includes North America and International. The Company's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. The Company manufactures and distributes its CoolSculpting system, including procedure packs, at its Dublin facility. The Livermore facility is used primarily for raw material storage. Through 2012 and the beginning of 2013, the Company has utilized OnCore Manufacturing LLC to manufacture and supply CoolSculpting system. ZELTIQ, CoolSculpting, and Company's logo are registered trademarks in the United States and in certain foreign countries. The design, development, manufacture, testing and sale of products are subject to regulation by governmental authorities, mainly FDA, and corresponding state and foreign regulatory agencies.
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
ZELTIQ to Participate at Investor Conferences in June 2015 May 20 2015 
Steven Cohen's Newest Buys, Additions and Reductions Mar 04 2015 
CoolSculpting(R) Procedure Named "Best Fat-Reducing Treatment" by NewBeauty(R) Magazine Jan 27 2015 
Steven Cohen Buys New Drug Stock, Triples Investment in Medical Company Jan 25 2015 
New Year, New You, New Findings -- New Survey Reveals What Women Expect to Gain by Keeping New Year' Jan 21 2015 
ZELTIQ to Present at J.P. Morgan 33rd Annual Healthcare Conference Jan 13 2015 
ZELTIQ to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan 05 2015 
ZELTIQ(R) Aesthetics Named Fastest Growing Medical Device Company in North America by Deloitte's 201 Nov 13 2014 
ZELTIQ Announces Conference Call and Webcast of Third Quarter 2014 Financial Results to Be Held on O Oct 15 2014 
ZELTIQ(R) Aesthetics Showcasing Its CoolSculpting(R) Procedure at Plastic Surgery The Meeting 2014 Oct 15 2014 

More From Other Websites
ZELTIQ to Participate at Investor Conferences in June 2015 May 20 2015
ZELTIQ to Participate at Investor Conferences in June 2015 May 20 2015
ZELTIQ(R) Aesthetics Reaches 2,000,000th CoolSculpting(R) Treatment Cycle Milestone May 14 2015
ZELTIQ(R) Aesthetics Reaches 2,000,000th CoolSculpting(R) Treatment Cycle Milestone May 14 2015
Zeltiq reports 1Q loss May 05 2015
Zeltiq reports 1Q loss May 05 2015
ZELTIQ Announces First Quarter 2015 Financial Results May 05 2015
ZELTIQ Aesthetics Inc Earnings Call scheduled for 4:30 pm ET today May 05 2015
ZELTIQ AESTHETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
ZELTIQ Announces First Quarter 2015 Financial Results May 05 2015
Q1 2015 ZELTIQ Aesthetics Inc Earnings Release - After Market Close May 05 2015
Five Stock Picks From Hedge Fund Sophrosyne Capital Apr 27 2015
ZELTIQ Announces Conference Call and Webcast of First Quarter 2015 Financial Results to Be Held on... Apr 21 2015
ZELTIQ Announces Conference Call and Webcast of First Quarter 2015 Financial Results to Be Held on... Apr 21 2015
Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies? Apr 17 2015
CoolSculpting(R) Procedure Named "Best Non-Surgical Procedure" by JEZEBEL Magazine Apr 08 2015
Why the Earnings Streak Will Continue for ZELTIQ Aesthetics (ZLTQ) - Tale of the Tape Mar 24 2015
ZELTIQ(R) Aesthetics Showcasing New CoolSmooth PRO(TM) Applicator at American Academy of Dermatology... Mar 19 2015
ZELTIQ(R) Aesthetics Showcasing New CoolSmooth PRO(TM) Applicator at American Academy of Dermatology... Mar 19 2015
Esperion Therapeutics Inc (ESPR), Cempra Inc (CEMP), Zeltiq Aesthetics Inc (ZLTQ): Aisling... Mar 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK